Administration of Ifosfamide-Doxorubicin Regimen (Days 1-3)
For a day 1-3 ifosfamide-doxorubicin regimen, administer ifosfamide 2500 mg/m² on days 1-3 with doxorubicin 60 mg/m² on day 1, repeated every 21 days, with mandatory mesna uroprotection totaling 100% of the ifosfamide dose. 1
Chemotherapy Dosing Schedule
Ifosfamide Administration
- Dose: 2500 mg/m² per day on days 1,2, and 3
- Route: Intravenous infusion over minimum 30 minutes 1
- Total per cycle: 7500 mg/m² over 3 days
- Cycle frequency: Every 21 days 1, 2
Doxorubicin Administration
- Dose: 60 mg/m² on day 1 only
- Route: 2-hour IV infusion 2
- Timing: Administer before or with ifosfamide on day 1
This regimen (often called "AIM" - Adriamycin/Ifosfamide/Mesna) demonstrates response rates of 12-34% in soft tissue sarcomas, with higher efficacy in specific histologies like synovial sarcoma 2, 3, 4.
Mandatory Mesna Uroprotection
Mesna is absolutely required with ifosfamide to prevent hemorrhagic cystitis, which occurs frequently without prophylaxis. 5, 1
FDA-Approved Mesna Regimen (Preferred)
The most practical approach combines IV and oral mesna 5:
- Day 1: Mesna 20% of ifosfamide dose (500 mg/m²) IV bolus at time of ifosfamide administration
- 2 hours after ifosfamide: Mesna 40% of ifosfamide dose (1000 mg/m²) orally
- 6 hours after ifosfamide: Mesna 40% of ifosfamide dose (1000 mg/m²) orally
- Repeat this schedule on days 2 and 3
- Total daily mesna: 100% of daily ifosfamide dose (2500 mg/m²)
Alternative All-IV Mesna Regimen
If oral administration is problematic 5:
- Mesna 60% of total daily ifosfamide dose (1500 mg/m²)
- Given as three IV bolus doses:
- 15 minutes before ifosfamide
- 4 hours after ifosfamide
- 8 hours after ifosfamide
- Repeat on each day of ifosfamide administration
Critical caveat: If patient vomits within 2 hours of oral mesna, repeat the oral dose or switch to IV mesna 5. This is essential as vomiting negates uroprotection.
Hydration Requirements
Aggressive hydration is mandatory to prevent urotoxicity 1:
- Minimum: 2 liters of oral or IV fluid per day during treatment
- Recommended IV hydration protocol:
- 300 mL/hour for 3 hours on day 1 before chemotherapy
- Then 100 mL/hour continuously for total of 3 days 6
Hematologic Support
Growth Factor Support
- Filgrastim (G-CSF): 5 mcg/kg subcutaneously daily for 14 days beginning day 3 of each cycle 6
- This significantly reduces severe neutropenia risk, which occurs in 82-92% of patients without support 7, 3
Pre-Treatment Requirements
Before each cycle, verify 1:
- WBC ≥ 4000/μL (some protocols use ≥2000/μL as absolute minimum)
- Platelets ≥ 100,000/μL (some use ≥50,000/μL as minimum)
- Hemoglobin adequate
Do not administer if counts below these thresholds unless clinically essential 1.
Monitoring During Treatment
Urinalysis Surveillance
- Obtain urinalysis before each dose 1
- If microscopic hematuria >10 RBCs per high-power field: Withhold subsequent doses until complete resolution
- Resume only with vigorous hydration 1
Hematologic Monitoring
- CBC with differential before each cycle
- Monitor at appropriate intervals during cycle
- Expect nadir around days 10-14
Neurologic Monitoring
Watch for CNS toxicity (somnolence, confusion, hallucinations, coma) - discontinue ifosfamide immediately if these occur 1. These symptoms are usually reversible with supportive care.
Preparation and Stability
Reconstitution 1
- 1 gram vial: Add 20 mL Sterile Water for Injection (final concentration 50 mg/mL)
- 3 gram vial: Add 60 mL Sterile Water for Injection (final concentration 50 mg/mL)
Further Dilution
May dilute to 0.6-20 mg/mL in:
- 5% Dextrose Injection
- 0.9% Sodium Chloride Injection
- Lactated Ringer's Injection
- Sterile Water for Injection
Storage: Refrigerate reconstituted/diluted solutions and use within 24 hours 1.
Expected Toxicities
Common Grade 3/4 Toxicities
- Neutropenia: 82-92% of patients 7, 3
- Leukopenia: 87% 8
- Lymphopenia: 57% 8
- Febrile neutropenia: Occurs in approximately 5-17% despite G-CSF 7, 9
- Nausea/vomiting: 13% grade 3/4 9
Treatment Discontinuation Rates
- 6% stop within first 2 cycles due to toxicity
- Additional 12% stop during later cycles
- 23% require dose modification 9
One critical warning: Treatment-related mortality occurs in approximately 1-3% of patients, primarily from sepsis or tumor lysis syndrome 2, 6. This regimen requires specialist supportive care infrastructure.
Efficacy Considerations
The evidence shows this regimen is most effective in:
- Synovial sarcoma: 80-88% disease control rate 2, 4, 9
- Uterine leiomyosarcoma: 17% response rate (vs 5% in non-uterine) 2
- High-grade soft tissue sarcomas >5 cm: Improved distant metastasis-free survival, disease-specific survival, and overall survival 4
Response rates are lower (5-12%) in other histologies and bone sarcomas show limited benefit 2, 10, 9.